Main | VISTA Clinical Trials

What is the Vista trial?

The Vista trial is studying an investigational (not yet approved for sale by government authorities like the FDA in the US or EMA in Europe) new gene therapy called AGTC-501 for patients with X-linked retinitis pigmentosa (XLRP).
The purpose of the Vista trial is to assess how well 2 different doses of AGTC-501 might work to preserve and/or improve vision and other symptoms of XLRP when compared to study participants who have not received AGTC-501.

What is XLRP?

XLRP is an inherited rare genetic eye disease in which light-sensitive cells in the retina (the thin layer of tissue that lines the inner surface of the back of the eye) do not function correctly.
XLRP can be caused by a mutation in a gene called Retinitis Pigmentosa GTPase Regulator (RPGR).
A change in RPGR can result in loss of vision due to degeneration (breakdown) of special cells in the retina called photoreceptors, which are needed for vision.

Who can participate in the Vista trial?

The Vista trial is for males between the ages of 12 and 50 who have X-linked retinitis pigmentosa (XLRP) caused by a mutation (or defect) in the RPGR gene. Individuals must meet certain criteria to qualify for the study.